Trial Profile
A Phase 2 Study of AZD6244 Plus Erlotinib for the Second-Line Treatment of Advanced Pancreatic Adenocarcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Selumetinib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 06 Aug 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 21 Nov 2014 Results presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
- 01 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.